EFTA01199408Set 9
2014-07-2313p8,089w
Synageva Biopharma Corp, Theravance Inc, Ultragenyx Pharmaceutical Inc, Versartis. Inc., Vertex Pharmaceuticals, XenoPort Inc.
Within the last 12 months. Morgan Stanley has received compensation for products and services other than ... Relypsa, Inc., Synageva Biopharma Corp, Theravance Inc. Ultragenyx Pharmaceutical Inc, Versartis, Inc., Vertex
Pharmaceuticals. XenoPort Inc.
Within the last 12 months. Morgan Stanley has either provided or is providing ... Pharmaceuticals Inc., Relypsa. Inc., Synageva Biopharma Corp, Theravance Inc. Versartis. Inc.. Vertex
Pharmaceuticals, XenoPort Inc.
The equity research analysts or strategists principally responsible for the preparation of Morgan Stanley
https://www.justice.gov/epstein/files/DataSet%209/EFTA01199408.pdf
EFTA00598607Set 9
2014-07-2313p8,093w
Synageva Biopharma Corp, Theravance Inc, Ultragenyx Pharmaceutical Inc, Versartis. Inc., Vertex Pharmaceuticals, XenoPort Inc.
Within the last 12 months. Morgan Stanley has received compensation for products and services other than ... Relypsa, Inc., Synageva Biopharma Corp, Theravance Inc. Ultragenyx Pharmaceutical Inc, Versartis, Inc., Vertex
Pharmaceuticals. XenoPort Inc.
Within the last 12 months. Morgan Stanley has either provided or is providing ... Pharmaceuticals Inc., Relypsa. Inc., Synageva Biopharma Corp, Theravance Inc. Versartis. Inc.. Vertex
Pharmaceuticals, XenoPort Inc.
The equity research analysts or strategists principally responsible for the preparation of Morgan Stanley
https://www.justice.gov/epstein/files/DataSet%209/EFTA00598607.pdf
EFTA00598622Set 9
14p8,563w
Synageva Biopharma Corp, Theravance Inc, Ultragenyx Pharmaceutical Inc, Versartis, Inc., Vertex Pharmaceuticals. XenoPort Inc.
Within the last 12 months. Morgan Stanley has received compensation for products and services other than ... Relypsa, Inc., Synageva Biopharma Corp, Theravance Inc. Ultragenyx Pharmaceutical Inc, Versartis, Inc., Vertex
Pharmaceuticals. XenoPort Inc.
Within the last 12 months. Morgan Stanley has either provided or is providing ... Pharmaceuticals Inc., Relypsa. Inc., Synageva Biopharma Corp. Theravance Inc. Versartis. Inc.. Vertex
Pharmaceuticals. XenoPort Inc.
The equity research analysts or strategists principally responsible for the preparation of Morgan Stanley
https://www.justice.gov/epstein/files/DataSet%209/EFTA00598622.pdf
EFTA01199422Set 9
14p8,572w
Synageva Biopharma Corp, Theravance Inc, Uftragenyx Pharmaceutical Inc, Versartis. Inc., Vertex Pharmaceuticals. XenoPort Inc.
Within the last 12 months. Morgan Stanley has received compensation for products and services other than ... Relypsa, Inc., Synageva Biopharma Corp, Theravance Inc. Ultragenyx Pharmaceutical Inc, Versartis, Inc., Vertex
Pharmaceuticals. XenoPort Inc.
Within the last 12 months. Morgan Stanley has either provided or is providing ... Pharmaceuticals Inc., Relypsa. Inc., Synageva Biopharma Corp. Theravance Inc. Versartis. Inc.. Vertex
Pharmaceuticals. XenoPort Inc.
The equity research analysts or strategists principally responsible for the preparation of Morgan Stanley
https://www.justice.gov/epstein/files/DataSet%209/EFTA01199422.pdf
EFTA01175291Set 9
2008-07-302p580w
otherwise,
11 including, but not limited to, Oxonica PLC Ordinary shares (private
placement) and Xenoport, Inc., and securities issued by Digital
12 Arts/Gallery Systems, Alivita, Inc., and Technogen Managers
https://www.justice.gov/epstein/files/DataSet%209/EFTA01175291.pdf
EFTA02697300Set 11
2008-07-302p594w
otherwise.
including, but not limited to, Oxonica PLC Ordinary shares (private
1i
placement) and Xenoport, Inc., and securities issued by Digital
12 Arts/Cralleay Systems, Alivita, Inc., and Technogen Managers
https://www.justice.gov/epstein/files/DataSet%2011/EFTA02697300.pdf
EFTA01840267Set 10
2008-07-302p592w
otherwise.
1i including, but not limited to, Oxonica PLC Ordinary shares (private
placement) and Xenoport, Inc., and securities issued by Digital
12 Arts/Galleay Systems, Alivita, Inc., and Tecimegen Managers
https://www.justice.gov/epstein/files/DataSet%2010/EFTA01840267.pdf